Friday, August 29, 2014 7:30:30 AM
The Ebola virus has mutated 300 times since the deadliest outbreak in history began in West Africa in May, and these transformations lead scientists to conclude that it is unlike any past Ebola epidemic. This could make it both harder to treat and harder to diagnose, according to a study published in Science magazine Thursday.
The outbreak began as a single human infection, the authors write, but the genetic sequences observed in the 78 patients sampled showed a rapid spread in both the number of people infected and the geographical regions affected. As it stands, the virus is unlike anything seen in the past, which will hinder the creation of treatments and make it difficult to fully contain the contagion, the study found.
“We’ve uncovered more than 300 genetic clues about what sets this outbreak apart from previous outbreaks,” said Stephen Gire, a co-author and disease researcher at Harvard.
The initial infection, contracted by a woman in Sierra Leone, came from one of five strains of Ebola known to affect humans called the Zaire strain. The Zaire strain came about a decade ago in a related strain from an animal host. Researchers are not positive which animal hosted the virus, but said it was most likely was a bat in Guinea. At least one species of fruit bat has a geographic range that spreads from Guinea to Sierra Leone. If bats are really the culprit, "about 150 million more people than previously thought are at risk of the disease," according to a previous study published in Science about Ebola.
The virus then crossed into Sierra Leone when the first woman diagnosed attended a funeral for someone who had recentely been in contact with Ebola in Guinea, the study found.
Since then, it “has exhibited sustained human-to-human transmission subsequently, with no evidence of additional zoonotic [animal] sources.”
One of the problems with this particular outbreak is that scientists have not been able to fully trace the virus from 2004 in Guinea to the current outbreak. Being unable to predict where it will next appear makes it very difficult to contain. The World Health Organization said Thursday that it hopes to stop the spread by 2015.
“We don’t actually know where the virus has been since then,” Pardis Sabeti, an associate professor at Harvard whose lab studied the Ebola genomes, told the Washington Post. “We’re trying to piece together an historical record.”
There is no cure for Ebola yet. On Thursday, an experimental Ebola vaccine made by UK-based pharmaceutical company GlaxoSmithKline was approved for testing on humans, but the results are not expected for at least a month.
Clues from Thursday’s study have scientists hopeful that nonstop research on mutations will help develop new diagnostic tests and treatments. “We've got to crowdsource the epidemic,” Sabeti said. “The more information you get into hands of people who can help, the more likely you are to come up with a solution.”
In the study, 99 Ebola samples were taken from 78 patients diagnosed with Ebola from May to late June. More than 50 people co-authored the study with help from Harvard University scientists and the Sierra Leone Health Ministry.
Five of the authors died before the paper was even published. Since May, Ebola has killed more than 1,400 people in four countries.
By Alessandria Masi@alessandriamasia.masi@ibtimes.com
on August 28 2014 11:07 PM
Recent CTSO News
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
- CytoSorbents to Report Third Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 10/27/2023 11:00:00 AM
- CytoSorbents to Present at the 8th Annual Dawson James Conference • GlobeNewswire Inc. • 10/05/2023 11:00:00 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM